Commentary | Published:

Reforming direct-to-consumer advertising

Nature Biotechnology volume 29, pages 397400 (2011) | Download Citation

Why not exploit direct-to-consumer advertising to facilitate patient education about treatments and improve safety monitoring?

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    N. Engl. J. Med. 346, 524–526 (2002).

  2. 2.

  3. 3.

    J. Am. Med. Assoc. 303, 311–313 (2010).

  4. 4.

    J. Law Med. Ethics 37, 444–450 (2009).

  5. 5.

  6. 6.

    Nat. Biotechnol. 24, 267 (2006).

  7. 7.

    Anonymous. Bulletin of the World Health Organization. 87 (2009). <>

  8. 8.

    Anonymous. Prescription Drugs: Improvements Needed in FDA's Oversight of Direct-to-Consumer Advertising. i–48 (US Government Accountability Office, Washington, DC, 2006). <>.

  9. 9.

    , & N. Engl. J. Med. 357, 673–681 (2007).

  10. 10.

    Anonymous. Impact of Direct-to-Consumer Advertising on Prescription Drug Spending (The Henry J. Kaiser Family Foundation, 2003). <>.

  11. 11.

    et al. Br. Med. J. 337, a1055 (2008).

  12. 12.

    et al. Intern. Med. J. 37, 224–228 (2007).

  13. 13.

    & Br. J. Clin. Pharmacol. 66, 626–628 (2008).

  14. 14.

    et al. Ann. Fam. Med. 5, 6–13 (2007).

  15. 15.

    et al. Am. J. Public Health 100, 24–32 (2010).

  16. 16.

    Nat. Biotechnol. 25, 267 (2007).

  17. 17.

    Pfizer broke the law by promoting drugs for unapproved uses. Bloomberg (9 November 2009). <>.

  18. 18.

    Anonymous. Drug Safety: FDA Has Begun Efforts to Enhance Postmarket Safety, but Additional Actions Are Needed. i–49 (US Government Accountability Office, Washington, DC, 2009).

  19. 19.

    Lawmakers seek to curb drug commercials. New York Times (27 July 2009). <>.

  20. 20.

    N. Engl. J. Med. 356, 2236–2239 (2007).

  21. 21.

    & Science 327, 273–274 (2010).

  22. 22.

    .

  23. 23.

    Anonymous Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modification. (US HHS, FDA, CDER, CBER, 2009) <>.

  24. 24.

    21 CFR 310.305.

  25. 25.

    Science 307, 196–198 (2005).

  26. 26.

    , & Health Aff. W4, 234–245 (2004).

  27. 27.

    N. Engl. J. Med. 321, 1405–1408 (1989).

Download references

Author information

Affiliations

  1. Bryan A. Liang is in the Department of Anesthesiology, San Diego Center for Patient Safety, University of California, San Diego School of Medicine, San Diego, California, USA.

    • Bryan A Liang
  2. Bryan A. Liang and Tim Mackey are at the Institute of Health Law Studies, California Western School of Law, San Diego, California, USA.

    • Bryan A Liang
    •  & Tim Mackey

Authors

  1. Search for Bryan A Liang in:

  2. Search for Tim Mackey in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Bryan A Liang.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.1865

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing